Bradmer Pharmaceuticals Inc. (TSE:GLX – Free Report) – Equities researchers at HC Wainwright reduced their Q1 2025 earnings estimates for shares of Bradmer Pharmaceuticals in a research report issued on Monday, March 31st. HC Wainwright analyst M. Colonnese now expects that the company will post earnings per share of ($0.76) for the quarter, down from their previous estimate of $0.47. HC Wainwright also issued estimates for Bradmer Pharmaceuticals’ Q2 2025 earnings at ($0.52) EPS, Q3 2025 earnings at $0.17 EPS, Q4 2025 earnings at $0.23 EPS and FY2025 earnings at ($0.76) EPS.
Other analysts have also recently issued reports about the company. Cantor Fitzgerald raised Bradmer Pharmaceuticals to a “strong-buy” rating in a research report on Tuesday, February 25th. Benchmark upgraded Bradmer Pharmaceuticals to a “strong-buy” rating in a research note on Monday.
Bradmer Pharmaceuticals Stock Performance
Featured Articles
- Five stocks we like better than Bradmer Pharmaceuticals
- Following Congress Stock Trades
- Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future
- How to Calculate Inflation Rate
- 5 Reasons the S&P 500 Could Rebound Strongly in 2025
- Ride Out The Recession With These Dividend Kings
- Best Gold Stocks in 2025… So Far
Receive News & Ratings for Bradmer Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bradmer Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
